TrialJapanese journal of clinical oncology2017

Efficacy and safety of sequential use of everolimus in Japanese patients with advanced renal cell carcinoma after failure of first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitor: a multicenter phase II clinical trial.

Masafumi Oyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.